However, LRRK2 is also abundantly expressed in kidneys, lungs, and immune cells, and inhibition of LRRK2 carries the risk of infections [306], but a phase I trial with DNL201, an LRRK2 inhibitor, raised no significant safety concerns [307]. This evidence concerns the gene LRRK2 and infection.